Rallybio Corp
For the period ended Mar 31, 2026. Filed May 13, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 13, 2026
RLYB$15.76+0.6%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss
Condensed Consolidated Statements of Operations and Comprehensive Loss
| FOR THE THREE MONTHS ENDED MARCH 31, | ||
|---|---|---|
| (in thousands, except share and per share amounts) | 2026 | 2025 |
| Revenue: | ||
| Collaboration and license revenue | $212 | $212 |
| Total revenue | 212 | 212 |
| Operating expenses: | ||
| Research and development | 2,871 | 5,725 |
| General and administrative | 6,074 | 4,157 |
| Total operating expenses | 8,945 | 9,882 |
| Loss from operations | (8,733) | (9,670) |
| Other income: | ||
| Interest income | 201 | 644 |
| Other income | 254 | 174 |
| Total other income, net | 455 | 818 |
| Loss before equity in losses of joint venture | (8,278) | (8,852) |
| Loss on investment in joint venture | — | 587 |
| Net loss | $(8,278) | $(9,439) |
| Net loss per common share, basic and diluted | $(1.46) | $(1.69) |
| Weighted-average common shares outstanding, basic and diluted | 5,688,584 | 5,597,528 |
| Other comprehensive loss: | ||
| Net unrealized loss on marketable securities | (17) | (21) |
| Other comprehensive loss | (17) | (21) |
| Comprehensive loss | $(8,295) | $(9,460) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.